the earnings whisper number of $0.72 per share is three cents above the consensus earnings estimate of $0.69 per share and is based, at least in part, on these comments (according to earningswhispers):
Eric J. Ende at Merrill Lynch said Gilead Sciences tracked ahead of estimates and he believes the company may post the biggest upside surprise in the Biotechnology industry. But, he cautions the company could increase its expense projections after its two recent acquisitions, which could offset the upside.
Geoffrey Porges at Sanford C. Bernstein said he expects strong Truvada sales will lead to Gilead Sciences beating current estimates.
Philip Nadeau at Cowen & Co. said he expects Gilead Sciences to beat estimates.
tick, tick, tick... up to $68.31 now.
It just keeps going up. It doesn't matter to me now as long as it stays above $65 until Feb 16, but I like it when I'm right and the higher it goes the more likely my trade will be right.